Aprea Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization6.46 mln

Float11.46 mln

Earnings Date11/05/2026

Piotroski F-Score

3 / 9

Below average

Beneish M-Score

-35.12

Highly reliable

1-Year Forecast

3.30

Transformational upside

Relative Strength

9 / 100

Severely lagging

Pre-Tax Margin

-237,363%

Severely loss-making

ROE

-50.87

Deeply negative

Business Description

Aprea Therapeutics is a Pennsylvania-based company working to bring new cancer treatments to patients. The company is currently testing two experimental drugs in early-stage clinical trials ? one targeting a protein called WEE1 and another targeting ATR ? both designed to fight solid tumors by disrupting the way cancer cells repair their DNA. Its approach focuses on exploiting specific weaknesses in cancer cells to slow or stop tumor growth.

Key Fundamentals

EPS-0.95

ROE-50.87

ROIC-1,289

ROA-44.60

EBITDA, mln-12.28

EV / EBITDA-0.15

EV / EBIT-0.15

Revenue, mln0.00

EV / Revenue381

Quote Details

Last 0.4846

Change -0.009 (-1.82%)

Open 0.4788

Volume 167,609

Turnover 81,223

Average Volume 216,404

Financial Ratios

Pre-Tax Profit Margin-237,363

Leverage Ratio1.10

Current Ratio13.55

Price / Book0.24

Price / Tangible Book0.24

Price / Sales17.05

Financial Strength

Altman Z-Score-9.25

Piotroski F-Score 3 / 9

Beneish M-Score-35.12

1-Year Target Price3.30

Short Ratio2.45

Short % of Float4.29

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-6.39%	14 / 100
1 Month	-33.02%	10 / 100
2 Months	-22.43%	21 / 100
6 Months	-40.76%	16 / 100
1 Year	-66.58%	13 / 100